HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study

NCT05167071 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
Neuroendocrine Tumors
CRC

Interventions

DRUG: HBM4003
DRUG: Toripalimab
DRUG: Tislelizumab

Sponsor

Harbour BioMed (Guangzhou) Co. Ltd.